Leptomeningeal Carcinomatosis Recruiting Phase 2 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0038074 (Leptomeningeal Carcinomatosis)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02939300Ipilimumab and Nivolumab in Leptomeningeal MetastasesTreatment